Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Use Of Protein Biomarkers Punctuates Clovis' Fast-Paced Clinical Trials Strategy

This article was originally published in Start Up

Executive Summary

A year ago, Clovis Oncology secured $145 million in start-up financing, the largest A round ever for a biotech. Now, the firm has mapped out a potential clinical trials and approval track for its first therapeutics program. And under a deal announced in April, development of that first drug, a lipid-conjugated formulation of the chemotherapy drug gemcitabine, will include a companion diagnostic developed and sold by Ventana Medical Systems.
Advertisement

Related Content

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091982

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel